Patient-Centered Dosing for Individuals with MBC

Unlike patients with early stage breast cancer whose disease is potentially curable and whose treatment period is limited, most patients with MBC will remain in treatment for the rest of their lives.

Whenever they begin a new treatment, patients with MBC are generally prescribed the same drug dosage as early stage breast cancer patients. This dosage is often based upon the Maximum Tolerated Dose (MTD), which is the highest dose that will not cause unacceptable toxicity. Nevertheless, as a result of treatment-related side effects, many patients with MBC experience a considerably diminished quality of life.

Since most drugs for MBC are available in several dosages, the Patient-Centered Dosing Initiative (PCDI) is building a framework to help physicians and patients select the optimal dosage for the patient based upon their unique physical, circumstantial, and psychological factors. Please join Dr. Aditya Bardia, medical oncologist at Massachusetts General Hospital (MGH) Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and Anne Loeser, patient advocate, author of The Insider's Guide to Metastatic Breast Cancer, and PCDI Founder as they further discuss Patient-Center Dosing for Individuals with MBC.